Randomized, double-blind, parallel group, phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)

  • Ing, Alvin (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Saghaie, Tajalli (Associate Investigator)
  • Rai, Meenal (Other)

Project: Research

Project Details

StatusNot started